Meriofert (Luteinising Hormone (Human), Follicle-Stimulating Hormone)

The LH component binds to LH receptors on theca cells, stimulating steroidogenesis and the production of estrogen and progesterone. The FSH component binds to FSH receptors on granulosa cells, promoting follicular growth, maturation of oocytes, and, in males, supporting Sertoli‑cell function for sperm development. Together they coordinate the hormonal cascade required for gamete maturation.

The dose of Meriofert is individualized and set by the prescribing clinician based on the patient’s hormonal profile, treatment protocol and response to therapy. Dosing regimens can vary widely between fertility centres and are adjusted according to ultrasound monitoring and serum hormone levels.

Meriofert is not indicated for use during an established pregnancy and should be discontinued once pregnancy is confirmed. Its safety in breastfeeding has not been established, and clinicians typically advise against use while nursing. Women of child‑bearing potential should use effective contraception until treatment is completed and pregnancy is excluded.

To order Meriofert, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details (including cold‑chain logistics if required) and any necessary import documentation.

Meriofert combines both LH and FSH in a single injectable, whereas many alternatives provide only recombinant FSH or urinary‑derived gonadotropins. The combined formulation can simplify dosing schedules and more closely mimic natural pituitary output, which may be advantageous in certain stimulation protocols. However, choice of product depends on individual patient response, clinic preference and cost considerations.

Meriofert must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. If the product is removed from refrigeration for a short period during administration, it should be returned to the cold chain promptly and used within the time frame specified by the manufacturer.

Meriofert is administered by injection, either intramuscularly or subcutaneously, according to the prescribing clinician’s instructions. The injection is typically performed in a clinical setting using aseptic technique. The exact site, volume and frequency depend on the treatment protocol and are tailored to the patient’s response monitored through ultrasound and hormone assays.

The most serious risks include ovarian hyperstimulation syndrome (OHSS), which can cause severe abdominal pain, fluid accumulation and thromboembolic complications; multiple pregnancy, which raises obstetric risks; and rare but severe allergic reactions such as anaphylaxis. Patients should be monitored closely for signs of these conditions, and treatment should be adjusted or discontinued if they occur.

Meriofert is contraindicated in women who are already pregnant, have known hypersensitivity to any component of the product, or have uncontrolled ovarian cysts or severe ovarian hyperstimulation syndrome. It should also be used with caution in patients with a history of thromboembolic disease, estrogen‑dependent tumors, or severe liver disease. The prescribing clinician must evaluate each patient’s medical history before initiating therapy.